摘要 |
The present invention relates to the combination of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one aromatase inhibitor and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. Aromatase inhibitors which can be combined together with the compound 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2 pentafluoroethyl)-estra-4,9-dien-3-one are for example aminoglutethimide, fadrozole, anastrozole, letrozole, vorozole, formestane, exemestane and atamestane.
|